Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S Van Sanden
Prm256 - Adjustment for the Impact of Subsequent Therapies Not Available in Uk on Overall Survival (Os) in Castor Trial: A Subgroup Analysis in Second-Line (2l) Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Assessing the Impact of Pegylated-Interferon/Ribavirin Therapy Duration Versus Viral Response on Health-Related Quality of Life (Qol) Outcomes in Chronic Hepatitis C Virus (Hcv) Patients, Using Multivariate Mixed-Effects Modeling
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Impact of Second-Line Treatment on Overall Survival of Advanced Lung Adenocarcinoma Patients
Prm118 - Adjustment for Subsequent Therapies Received: The Impact on Outcomes of an Economic Model of Nivolumab+ipilimumab in First Line Renal Cell Carcinoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Figure 3: Survival Analysis of CELSR3 Expression in Terms of Overall Survival (OS).
Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma
Urology
Urology
Pre-Operative Tracheostomy Does Not Impact on Stomal Recurrence and Overall Survival in Patients Undergoing Primary Laryngectomy
European Archives of Oto-Rhino-Laryngology
Medicine
Otorhinolaryngology
Increased Risk of Second Primary Hematologic and Solid Malignancies in Patients With Mycosis Fungoides: Impact on Overall Survival in Seer Registry
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
PDB21 Chart Audit and Budget Impact Analysis of Pasireotide Versus Second-Line Therapies in the Treatment of Cushing's Disease in Germany
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Impact of Increasing Dose on Overall Survival in Prostate Cancer
Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
Figure 5: Survival Curves for DEmRNAs That Are Associated With the Overall Survival (OS) of LUSC Patients.
